The PELICAN (Project to ELIminate lethal CANcer) Personalized Cancer Medicine group is focused on performing deep integrated clinical-molecular studies of high-risk and metastatic prostate cancer. By using combined clinical and phylogenetic analysis in tissue, blood, and other body fluids, we have contributed to understanding the evolution of lethal prostate cancer, and we are performing combined basic science and clinical trials to develop improved, personalized methods to provide benefit to prostate cancer patients and improved decision support for the physicians and others who care for prostate cancer patients.